JP Morgan Chase’s BioTelemetry, Inc. BEAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-96,519
Closed -$6.96M 6580
2020
Q4
$6.96M Sell
96,519
-24,844
-20% -$1.3M ﹤0.01% 2516
2020
Q3
$5.45M Sell
121,363
-139,626
-53% -$5.84M ﹤0.01% 2497
2020
Q2
$11.8M Sell
260,989
-10,978
-4% -$492K ﹤0.01% 1763
2020
Q1
$10.5M Buy
271,967
+52,743
+24% +$2.43M ﹤0.01% 1705
2019
Q4
$10.1M Sell
219,224
-30,597
-12% -$1.32M ﹤0.01% 2101
2019
Q3
$10.2M Buy
249,821
+10,110
+4% +$437K ﹤0.01% 2128
2019
Q2
$11.5M Buy
239,711
+127,508
+114% +$6.7M ﹤0.01% 1992
2019
Q1
$7.03M Buy
112,203
+8,277
+8% +$569K ﹤0.01% 2329
2018
Q4
$6.21M Buy
103,926
+60,760
+141% +$3.65M ﹤0.01% 2403
2018
Q3
$2.78M Sell
43,166
-15,680
-27% -$875K ﹤0.01% 3223
2018
Q2
$2.65M Sell
58,846
-37,186
-39% -$1.48M ﹤0.01% 3184
2018
Q1
$2.98M Buy
96,032
+67,002
+231% +$2.2M ﹤0.01% 2993
2017
Q4
$868K Buy
29,030
+6,666
+30% +$193K ﹤0.01% 3799
2017
Q3
$721K Sell
22,364
-37,227
-62% -$1.29M ﹤0.01% 3680
2017
Q2
$1.99M Sell
59,591
-27,885
-32% -$832K ﹤0.01% 3047
2017
Q1
$2.53M Sell
87,476
-53,762
-38% -$1.33M ﹤0.01% 2895
2016
Q4
$3.16M Buy
141,238
+72,785
+106% +$1.42M ﹤0.01% 2791
2016
Q3
$1.27M Buy
+68,453
New +$1.29M ﹤0.01% 3018
2015
Q3
Sell
-241,600
Closed -$2.28M 4314
2015
Q2
$2.28M Sell
241,600
-17,900
-7% -$166K ﹤0.01% 2837
2015
Q1
$2.3M Buy
+259,500
New +$2.62M ﹤0.01% 2803
2014
Q3
Sell
-49,796
Closed -$357K 4401
2014
Q2
$357K Buy
49,796
+4,397
+10% +$35K ﹤0.01% 3226
2014
Q1
$458K Buy
45,399
+34,322
+310% +$316K ﹤0.01% 3163
2013
Q4
$88K Buy
+11,077
New +$103K ﹤0.01% 3923

Other funds holding BEAT

JP Morgan Chase's BEAT Position: Q1 2021 in Review

JP Morgan Chase sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 96,519 shares — an estimated $6.96M sold.

JP Morgan Chase first reported a position in BEAT in Q4 2013 and held it in 23 quarters. The position peaked at $11.8M in Q2 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • JP Morgan Chase reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • JP Morgan Chase sold 96,519 BioTelemetry, Inc. shares in Q1 2021, an estimated $6.96M.
  • JP Morgan Chase first reported a position in BioTelemetry, Inc. in Q4 2013 and held it in 23 quarters.
  • JP Morgan Chase's BioTelemetry, Inc. position peaked at $11.8M in Q2 2020.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on JP Morgan Chase's 13F filing for Q1 2021, filed 12 May 2021.